EP0692931A4 - Synthetic matrix metalloprotease inhibitors and uses thereof - Google Patents

Synthetic matrix metalloprotease inhibitors and uses thereof

Info

Publication number
EP0692931A4
EP0692931A4 EP94913345A EP94913345A EP0692931A4 EP 0692931 A4 EP0692931 A4 EP 0692931A4 EP 94913345 A EP94913345 A EP 94913345A EP 94913345 A EP94913345 A EP 94913345A EP 0692931 A4 EP0692931 A4 EP 0692931A4
Authority
EP
European Patent Office
Prior art keywords
matrix metalloprotease
metalloprotease inhibitors
synthetic matrix
synthetic
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94913345A
Other languages
German (de)
French (fr)
Other versions
EP0692931A1 (en
Inventor
Richard Edward Galardy
Damian Grobelny
Gregory Scott Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycomed Inc
Original Assignee
Glycomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed Inc filed Critical Glycomed Inc
Publication of EP0692931A1 publication Critical patent/EP0692931A1/en
Publication of EP0692931A4 publication Critical patent/EP0692931A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP94913345A 1993-04-07 1994-04-01 Synthetic matrix metalloprotease inhibitors and uses thereof Ceased EP0692931A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4432493A 1993-04-07 1993-04-07
US44324 1993-04-07
PCT/US1994/003600 WO1994022309A1 (en) 1993-04-07 1994-04-01 Synthetic matrix metalloprotease inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
EP0692931A1 EP0692931A1 (en) 1996-01-24
EP0692931A4 true EP0692931A4 (en) 1996-03-20

Family

ID=21931747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94913345A Ceased EP0692931A4 (en) 1993-04-07 1994-04-01 Synthetic matrix metalloprotease inhibitors and uses thereof

Country Status (5)

Country Link
EP (1) EP0692931A4 (en)
JP (1) JPH08511509A (en)
AU (1) AU6554294A (en)
CA (1) CA2160139A1 (en)
WO (1) WO1994022309A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
EP0934259B1 (en) * 1996-10-16 2002-09-18 American Cyanamid Company Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
EP0938548B1 (en) 1996-11-06 2008-08-06 The Regents of the University of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US20040235950A1 (en) * 1999-05-20 2004-11-25 Voorhees John J. Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
EP1372692A4 (en) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
AU2004263900A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005086915A2 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
JP5421238B2 (en) * 2008-03-13 2014-02-19 株式会社ヤクルト本社 MMP inhibitor
KR20170086678A (en) * 2012-05-21 2017-07-26 디씨비-유에스에이 엘엘씨 Methods for drug screen using zebrafish model and the compounds screened therefrom

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489579A1 (en) * 1990-12-03 1992-06-10 Celltech Therapeutics Limited Peptidyl derivatives
WO1992009563A1 (en) * 1990-11-21 1992-06-11 Glycomed, Inc. Improved matrix metalloprotease inhibitors
WO1992009556A1 (en) * 1990-11-21 1992-06-11 Galardy Richard E Improved matrix metalloprotease inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
WO1991017982A1 (en) * 1990-05-21 1991-11-28 Sankyo Company, Limited Novel compound matristatin
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009563A1 (en) * 1990-11-21 1992-06-11 Glycomed, Inc. Improved matrix metalloprotease inhibitors
WO1992009556A1 (en) * 1990-11-21 1992-06-11 Galardy Richard E Improved matrix metalloprotease inhibitors
EP0489579A1 (en) * 1990-12-03 1992-06-10 Celltech Therapeutics Limited Peptidyl derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9422309A1 *

Also Published As

Publication number Publication date
WO1994022309A1 (en) 1994-10-13
EP0692931A1 (en) 1996-01-24
JPH08511509A (en) 1996-12-03
CA2160139A1 (en) 1994-10-13
AU6554294A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
ZA959948B (en) Matrix metalloprotease inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
HUP9903014A3 (en) Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
GB9422158D0 (en) N-acylindoles and related compounds
SG44363A1 (en) Pseudorandom function and the use thereof for encryption
GB2277050B (en) Dimple-forming and fastener-driving tool
ZA947833B (en) 4-Arylamino-benzopyran and related compounds
EP0692931A4 (en) Synthetic matrix metalloprotease inhibitors and uses thereof
EP0734398A4 (en) Compounds and methods
KR970009885B1 (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammtory agent
EP0722321A4 (en) Sulfoximine and sulfodiimine matrix metalloproteinase inhibitors
GB2281830B (en) I/q-modulator and i/q-demodulator
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
HU9502968D0 (en) 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors
GB9501907D0 (en) Allatostatins and their use
GB9306456D0 (en) Composition and use
ZA9610604B (en) Matrix metalloprotease inhibitors
ZA949525B (en) Enzyme inhibitors
GB9408859D0 (en) Composition and use
GB9323850D0 (en) Protease inhibitors
GB9308091D0 (en) Compounds and use
GB9311223D0 (en) Compounds and use
GB9302342D0 (en) Compounds and methods
GB9319147D0 (en) Compounds and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07D209/20

A4 Supplementary search report drawn up and despatched

Effective date: 19960131

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981102

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APBJ Interlocutory revision of appeal recorded

Free format text: ORIGINAL CODE: EPIDOS IRAPE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20010114

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE